Show simple item record

dc.contributor.author Mucci, Armida
dc.contributor.author Vignapiano, Annarita
dc.contributor.author Bitter, István
dc.contributor.author Austin, Stephen F
dc.contributor.author Delouche, Camille
dc.contributor.author Dollfus, Sonia
dc.contributor.author Erfurth, Andreas
dc.contributor.author Fleischhacker, W Wolfgang
dc.contributor.author Giordano, Giulia M
dc.contributor.author Gladyshev, Igor
dc.contributor.author Glenthøj, Birte
dc.contributor.author Gütter, Karoline
dc.contributor.author Hofer, Alex
dc.contributor.author Hubeňák, Jan
dc.contributor.author Kaiser, Stefan
dc.contributor.author Libiger, Jan
dc.contributor.author Melle, Ingrid
dc.contributor.author Nielsen, Mette Ø
dc.contributor.author Papsuev, Oleg
dc.contributor.author Rybakowski, Janusz K
dc.contributor.author Sachs, Gabriele
dc.contributor.author Üçok, Alp
dc.contributor.author Wojciak, Pawel
dc.contributor.author Galderisi, Silvana
dc.date.accessioned 2021-06-08T07:56:06Z
dc.date.available 2021-06-08T07:56:06Z
dc.date.issued 2019
dc.identifier.citation journalVolume=29;journalIssueNumber=8;journalTitle=EUROPEAN NEUROPSYCHOPHARMACOLOGY;pagerange=947-959;journalAbbreviatedTitle=EUR NEUROPSYCHOPHARM;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/7388
dc.identifier.uri doi:10.1016/j.euroneuro.2019.05.006
dc.description.abstract Negative symptoms represent an unmet need of treatment in schizophrenia. Although a consensus exists on negative symptom construct, and second generation assessment instruments reflecting the consensus are available, studies still rely upon old assessment instruments, that do not reflect recent conceptualizations and might limit progress in the search for effective treatments. This is often the case in the European context, where one of the challenges encountered in designing large studies is the availability of validated instruments in the many languages of the continent. To address this challenge and promote sound research on negative symptoms in Europe, the ECNP Schizophrenia Network coordinated a large multicenter, multinational validation study of the Brief Negative Symptom Scale (BNSS). Clinically-stable subjects with schizophrenia (SCZ, N = 249) were recruited from 10 European Countries. Apart from BNSS, subjects were administered the Positive and Negative Syndrome Scale (PANSS) and standardized instruments for depression, extrapyramidal symptoms and psychosocial functioning. Results showed an excellent internal consistency, convergent and discriminant validity of BNSS and replicated a 5 factor-model. A larger number of subjects with predominant negative symptoms, i.e. the target population for clinical trials, was identified by using the BNSS compared to the PANSS. Regression analysis showed that BNSS-avolition, a key negative symptom poorly assessed by PANSS, explained 23.9% of psychosocial functioning, while no combination of the PANSS core negative symptoms showed the same impact on functioning. The study demonstrated that BNSS has substantial advantages with respect to PANSS for the identification of the avolition domain and subjects with predominant negative symptoms.
dc.relation.ispartof urn:issn:0924-977X
dc.title A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale
dc.type Journal Article
dc.date.updated 2019-08-02T08:16:26Z
dc.language.rfc3066 en
dc.rights.holder NULL
dc.identifier.mtmt 30747432
dc.identifier.pubmed 31255394
dc.contributor.department SE/AOK/K/Pszichiátriai és Pszichoterápiás Klinika
dc.contributor.institution Semmelweis Egyetem


Files in this item

This file is available only from Semmelweis network

View/Open

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account